1. Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study 
Matti Kivikko, MD, PhD, Mikko Kuoppamäki, MD, PhD, Lauri Soinne, MD, PhD, Stig Sundberg, PhD, Pasi Pohjanjousi, MSc, Juha Ellmen, PhD, Risto O. Roine, MD, PhD 
Current Therapeutic Research 
Volume 77, Pages (December 2015)
DOI: /j.curtheres
Copyright © 2015 The Authors Terms and Conditions

2. Figure 1
Subject disposition. Period 5 refers to dose level 1mg daily and period 6 to dose level 2mg daily.
Current Therapeutic Research  , 46-51DOI: ( /j.curtheres )
Copyright © 2015 The Authors Terms and Conditions

3. Figure 2
Mean (SD) blood flow velocities of the middle cerebral artery at different dose levels. (*<0.05).
Current Therapeutic Research  , 46-51DOI: ( /j.curtheres )
Copyright © 2015 The Authors Terms and Conditions

4. Figure 3
Statistical model based estimates (and 90% CI) for the levosimendan/placebo ratio of the number of VES/h.
Current Therapeutic Research  , 46-51DOI: ( /j.curtheres )
Copyright © 2015 The Authors Terms and Conditions

5. Figure 4 Median NT-pro-BNP values during the study.
Current Therapeutic Research  , 46-51DOI: ( /j.curtheres )
Copyright © 2015 The Authors Terms and Conditions

6. Figure 5
Mean (SD) plasma concentrations of levosimendan metabolites OR-1855 and OR-1896 at the end of each dosing period.
Current Therapeutic Research  , 46-51DOI: ( /j.curtheres )
Copyright © 2015 The Authors Terms and Conditions